Who Paid My Doc
Peter Kurzweil
Long Beach, CA Medical Doctor
NPI 1700865466 CMS profile 77473
2760 Atlantic Ave, Long Beach, CA 90806
General payments
$494,119
Research payments
$0
Ownership & investment interest
$1,071,576
Through program year 2024, Peter Kurzweil of Long Beach, CA is reported in the CMS Open Payments database as having received $494,119 across 91 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $1,071,576 across 1 holding.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $15 | 1 | |
| 2023 | General | $166 | 4 | |
| 2022 | General | $56,306 | 4 | |
| 2021 | General | $247 | 11 | |
| 2020 | General | $428,105 | 38 | |
| 2019 | General | $9,279 | 33 | |
| 2019 | Ownership | $1,071,576 | 1 |
Beside peers
- Peter Kurzweil
- California median
- Middle half of California
- National median
In program year 2025, general payments to Peter Kurzweil were reported at $0. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.
Show as a table
| Year | Peter Kurzweil | California median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $9,279 | $161 | $50–$652 | $163 |
| 2020 | $428,105 | $114 | $34–$392 | $114 |
| 2021 | $247 | $137 | $41–$509 | $132 |
| 2022 | $56,306 | $152 | $48–$573 | $149 |
| 2023 | $166 | $162 | $50–$581 | $160 |
| 2024 | $15 | $162 | $52–$583 | $164 |
| 2025 | $0 | $172 | $54–$610 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
1,059
Drug cost
$8,262
Branded share of claims
10.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Celecoxib | Generic | 123 | $3,764 | |
| Meloxicam | Generic | 519 | $1,351 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 91 | $1,191 | |
| Cephalexin | Generic | 104 | $568 | |
| Diclofenac Sodium | Generic | 25 | $383 | |
| Ibuprofen | Generic | 13 | $251 | |
| Omeprazole | Generic | 64 | $238 | |
| Diclofenac Sodium Er Diclofenac Sodium | Brand | 17 | $215 | |
| Prednisone | Generic | 74 | $203 | |
| Gabapentin | Generic | 18 | $65 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 41 billing codesPaid by Medicare
$755,284
Medicare patients
949
Services billed
21,351
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 68% | |
| Ischemic heart disease | 22% | |
| Osteoporosis | 20% | |
| Diabetes | 19% | |
| Chronic kidney disease | 18% | |
| Depression | 17% | |
| Atrial fibrillation | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 | Office | 222 | 17,280 | $230,451 |
| Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 | Office | 182 | 333 | $134,839 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 24 | 139 | $746 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
91 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.